AstraZeneca's Alexion Unit Gains FDA Nod for Ultomiris in IgAN, Ticker AZN
· gurufocus.com
On October 21, 2026, AstraZeneca PLC (NYSE: AZN) announced that its Alexion Rare Disease division received U.S. FDA approval for Ultomiris (ravulizumab) to redu
On October 21, 2026, AstraZeneca PLC (NYSE: AZN) announced that its Alexion Rare Disease division received U.S. FDA approval for Ultomiris (ravulizumab) to redu...